文献速递淋巴瘤

滤泡性淋巴瘤:2018年诊断与管理更新

Follicular lymphoma: 2018 update on diagnosis and management.
PubMed 文献 · Am J Hematol · 2018-01-01

滤泡性淋巴瘤是一种惰性B细胞淋巴增殖性疾病,诊断基于淋巴结活检组织学及免疫组化(CD19、CD20、CD10、单克隆免疫球蛋白、bcl-2阳性)和t(14;18)易位。风险分层采用FLIPI模型(年龄>60岁、血红蛋白<12 g/dL、血清LDH>正常、Ann Arbor III/IV期、受累淋巴结区域>4个)。无症状低肿瘤负荷且无血细胞减少者观察即可,需治疗者以化疗联合利妥昔单抗为主,维持利妥昔单抗有额外获益。

要点

  • 诊断首选淋巴结活检组织学,免疫组化几乎均表达CD19、CD20、CD10、单克隆免疫球蛋白及bcl-2。
  • FLIPI采用5项独立不良预后因素:年龄>60岁、血红蛋白<12 g/dL、LDH>正常、III/IV期、淋巴结区域>4个。
  • 无症状低肿瘤负荷且无血细胞减少者观察即可,早期化疗或单用利妥昔单抗无生存优势。

核心结论

  • 无症状低肿瘤负荷且无血细胞减少的患者观察继续是足够的,早期化疗或单用利妥昔单抗均无生存优势。
  • 需要治疗的患者多数接受化疗联合利妥昔单抗,提高了缓解率、缓解持续时间和总生存。
  • 随机研究显示,化疗-利妥昔单抗后及单药利妥昔单抗后维持利妥昔单抗均有额外获益。
  • 复发疾病考虑实验性治疗及干细胞移植。

研究设计与样本

  • 本文为滤泡性淋巴瘤诊断与管理更新综述。

主要发现

  • 滤泡性淋巴瘤一般为惰性B细胞淋巴增殖性疾病,特征为弥漫性淋巴结病、骨髓受累、脾肿大,较少累及其他结外部位。
  • 血细胞减少可发生,但发热、盗汗、体重减轻等体质性症状不常见。
  • 免疫组化几乎在所有病例中细胞表面CD19、CD20、CD10及单克隆免疫球蛋白阳性,胞质bcl-2蛋白表达阳性。
  • 绝大多数病例具有涉及IgH/bcl-2基因的特征性t(14;18)易位。
  • FLIPI采用5项独立不良生存预测因素:年龄>60岁、血红蛋白<12 g/dL、血清LDH>正常、Ann Arbor III/IV期、受累淋巴结区域数>4。

关键数值与推荐

  • FLIPI的5项独立不良生存预测因素:年龄>60岁、血红蛋白<12 g/dL、血清LDH>正常、Ann Arbor III/IV期、受累淋巴结区域数>4。
  • 0、1、2和≥3个不良因素分别定义为低危、中危和高危疾病。
  • 免疫组化几乎均阳性:细胞表面CD19、CD20、CD10、单克隆免疫球蛋白,以及胞质bcl-2蛋白。

临床怎么用

  • 无症状低肿瘤负荷且无血细胞减少的患者观察继续是足够的。
  • 需要治疗的患者多数接受化疗联合利妥昔单抗。
  • 随机研究显示化疗-利妥昔单抗后及单药利妥昔单抗后维持利妥昔单抗均有额外获益。
  • 复发疾病考虑实验性治疗及干细胞移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. In general, cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon. DIAGNOSIS: Diagnosis is based on histology of preferably a biopsy of a lymph node. Immunohistochemical staining is positive in virtually all cases for cell surface CD19, CD20, CD10, and monoclonal immunoglobulin, as well as cytoplasmic expression of bcl-2 protein. The overwhelming majority of cases have the characteristic t(14;18) translocation involving the IgH/bcl-2 genes. RISK STRATIFICATION: The Follicular Lymphoma International Prognostic Index prognostic model for FL uses five independent predictors of inferior survival: age >60 years, hemoglobin <12 g/dL, serum LDH > normal, Ann Arbor stage III/IV, number of involved nodal areas > 4. The presence of 0, 1, 2, and ≥ 3 adverse factors defines low, intermediate, and high-risk disease. With the use of more modern therapies, outcomes have improved. RISK-ADAPTED THERAPY: Observation continues to be adequate for asymptomatic patients with low bulk disease and no cytopenias, with no survival advantage for early treatment with either chemotherapy or rituximab alone. For patients needing therapy, most patients are treated with chemotherapy plus rituximab, which has improved response rates, duration of response and overall survival. Randomized studies have shown additional benefit for maintenance rituximab both following chemotherapy-rituximab and single agent rituximab. Experimental therapies as well as stem cell transplantation (SCT) are considered for recurrent disease.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018. PMID: 29314206. doi:10.1002/ajh.24937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。